Clinical Trials Logo

Sjogren's Syndrome clinical trials

View clinical trials related to Sjogren's Syndrome.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 3

NCT ID: NCT03614299 Not yet recruiting - Clinical trials for Primary Sjögren Syndrome

Eye Dryness Evaluation in Primary Sjögren's Syndrome

PEPSS
Start date: October 1, 2019
Phase:
Study type: Observational

The objective of this observational study is to develop new tools to assess primary Sjögren's syndrome (pSS) symptoms and to measure the severity of eye involvement in these patients.

NCT ID: NCT03140111 Not yet recruiting - Dry Eye Syndromes Clinical Trials

LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients

Start date: October 16, 2017
Phase: N/A
Study type: Interventional

Single-blind, randomised, single centre, 2-way crossover pilot study to investigate the effectiveness of LAMELLEYE for the treatment of dry eye symptoms in patients with primary Sjögren's Syndrome.

NCT ID: NCT03126383 Not yet recruiting - Clinical trials for Primary Sjögren Syndrome

Inflammatory Myopathies in Primary Sjögren's Syndrome

AMISS
Start date: May 10, 2017
Phase: N/A
Study type: Observational

The AMISS study will characterize the features of muscle disease in patients with primary Sjogren's syndrome (pSS).

NCT ID: NCT02691377 Not yet recruiting - Sjogren's Syndrome Clinical Trials

Acupuncture for Primary Sjögren Syndrome

Start date: March 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether acupuncture is effective and safe in the treatment of Primary Sjögren Syndrome.

NCT ID: NCT02381587 Not yet recruiting - Clinical trials for Primary Sjogren Syndrome With Multisystem Involvement

the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Sjogren Syndrome Patients

HAS
Start date: April 2015
Phase: N/A
Study type: Observational

sjogren syndrome is an autoimmune disease that mainly affects the Salivary glands and Lacrimal gland In addition to the effects of this disease is characterized by overall systemic Muskals injury, pulmonary disease, peripheral neuropathy and vasculitis. In addition recent studies have shown that patients are at increased risk of the disease up to 2 cardiac events and stroke events Hydroxychloroquine is an RHEUMATIC DISEASE PROCESS SUPPRESSANTS-ANTIMALARIALS used to treat anti-inflammatory rheumatic diseases in many first-line treatment is sjogren syndrome. A recent study of the treatment in Hydroxychloroquine effect on lipid profile sjogren syndrome patients showed a reduction in total cholesterol levels and increase in HDL. Further studies of the impact made Hydroxychloroquine systemic lupus patients erythematosus (SLE) showed in Atherosclerosis and morbidity and mortality reduction in cardiovascular. Studies of patients with rheumatoid arthritis (RA) demonstrated reduced risk of developing diabetes and improved lipid profile Research Goals valuate The effect of HCQ treatment in cardiovascular patients with primary sjogren syndrome